Aethlon Medical stock analysis
Aethlon Medical (0A6R) Share Price & Analysis
0A6R Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- EUR 7.09M
- Enterprise Value
- EUR 300.27K
- Total Cash (Recent Filing)
- EUR 6.49M
- Total Debt (Recent Filing)
- EUR 172.12K
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- Feb 15, 2027 (Est.)
- EPS Estimate
- -1.55
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Clinical Progress
Advancement into the final oncology cohort and repeatable directional biomarker changes provide important clinical-development progress. While not proof of efficacy, persistence across follow-up supports continued evaluation of the Hemopurifier and could strengthen future regulatory and partnering discussions.
Platform Expansion
Expansion across multiple disease areas increases the potential addressable use cases for the Hemopurifier rather than relying on a single indication. Continued preclinical work, mechanism-focused findings and intellectual-property development can support longer-term partnering and clinical optionality.
Runway And Cost Control
Recent financing combined with lower operating expenses gives Aethlon additional time to complete its current clinical work and analyze results. Extending runway while reducing spending can improve execution discipline, although the company remains dependent on future capital for larger development programs.
Bears Say
Persistent Operating Losses
The absence of meaningful recent revenue and persistent operating losses show that the business has not yet reached commercial self-sufficiency. Continued negative cash generation limits internal funding capacity and makes progress dependent on financing, partnerships or eventual successful commercialization.
Clinical Uncertainty
Small cohorts and pending statistical analysis substantially limit confidence in the reproducibility, efficacy and generalizability of the biomarker findings. Until larger studies establish clinical benefit, the Hemopurifier remains exposed to validation risk and may face difficulty securing broad regulatory or commercial support.
Merger Dilution And Transition
The proposed transaction materially changes Aethlon investors' economic exposure and strategic direction, with North Immunology shareholders expected to own most of the combined company. Winding down certain legacy activities could also reduce the direct future influence and upside of the Hemopurifier program.
Aethlon Medical News
M&A News: Aethlon Medical Stock (AEMD) Rockets 400% After North Immunology Deal to Fight Eczema
Aethlon Medical ($AEMD) shares were nearly 400% higher in pre-market trading today after it announced it was merging with North Immunology to drive forward its innovative eczema treatment. Aethlon said
0A6R FAQ
What is Aethlon Medical’s market cap?
When is Aethlon Medical’s upcoming earnings report date?
How were Aethlon Medical’s earnings last quarter?
Is Aethlon Medical overvalued?
Does Aethlon Medical pay dividends?
What is Aethlon Medical’s EPS estimate?
What happened to Aethlon Medical’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Aethlon Medical?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Aethlon Medical
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- James Frakes
- Employees
- 9
- Website
- www.aethlonmedical.com
- Address
- 11555 Sorrento Valley Road, San Diego, CA, 92121, US
Aethlon Medical (0A6R) Earnings & Revenues
0A6R Earnings Call
Earnings Call SentimentNeutral
The call balanced tangible near-term progress with clear caveats. Positives include advancement into the final clinical cohort, encouraging Cohort 2 biomarker signals, a peer-reviewed Long COVID preclinical publication, ongoing R&D expansion, an improved post-quarter cash position following a ~$4.0M financing, and an 11.9% reduction in operating expenses. Key negatives are that clinical observations are preliminary and based on very small sample sizes, statistical analyses are pending, dosing is logistically constrained, and larger trials will require additional capital or partnerships. Overall, the company shows disciplined resource management and meaningful early scientific signals but faces validation, scale and funding headwinds before efficacy or regulatory clarity can be established.
View all GB:0A6R earnings summaries









